GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the risk of heart attack, second strokes and death ...

A version of the MESA heart disease risk score that did not include race predicted heart disease risk just as well as the version that includes race, according to a preliminary study presented today ...

New studies to be presented at the American Heart Association meeting focus on disparities in Wegovy prescriptions and ...

Stroke was the fourth leading cause of death in the U.S. in 2023, according to the Centers for Disease Control and Prevention ...